Zanamivir Suppliers & Bulk Manufacturers
Available Forms: Inhalation powder
Available Strengths: 5 mg/blister
Reference Brands: Relenza(EU & US)
Category:
Anti Viral
Zanamivir (Relenza) is an inhaled antiviral used to treat and prevent Influenza A and B. It’s effective when used early and is approved for adults and children via a Diskhaler device.
Zanamivir is available in Inhalation powder
and strengths such as 5 mg/blister.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Zanamivir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Zanamivir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Zanamivir, marketed under the brand name Relenza, is an FDA- and EMA-approved antiviral drug used for the treatment and prevention of Influenza A and B. As a neuraminidase inhibitor, Zanamivir prevents the release of new virus particles from infected cells, reducing flu severity and duration when started within 48 hours of symptoms. It is administered via oral inhalation using a Diskhaler, with each dose delivering 10 mg (two 5 mg blisters). Zanamivir is approved for use in adults and children (≥7 years for treatment, ≥5 for prevention). Relenza offers a localized delivery option with minimal systemic side effects.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing